🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — May 13, 2026

The 15 filings reveal a vibrant SPAC ecosystem with 12/15 involving blank-check companies advancing through IPOs (West Enclave, Starlink AI), unit separations (Maywood, Inflection Point), deadline extensions (Aquaron to 2027, GP-Act III to Nov 2026, Future Vision to June 2026, SIM to July 2027), and merger amendments (Live Oak V, FG Merger II), signaling sustained M&A pursuit amid avoiding liquidations. A standout airline sector consolidation: Allegiant Travel completed its $140M-synergy acquisition of Sun Country on May 13, 2026, forming a leisure airline giant with 195 aircraft and EPS accretion in year 1, while Sun Country delisted. M3-Brigade's proxy for ReserveOne de-SPAC targets June 15 EGM with PIPE at ~$500M valuation. One termination (Iris Acquisition Corp II LOI with Freedom Metals) stands out negatively. Target A&B Aerospace (PMGC) showed strong YoY trends: 9-mo revenue +12.8% to $3.6M, 3-mo +25.5% to $1.3M, net income swing to profit. No insider trading or capital allocation shifts noted across filings; portfolio trend shows SPAC extensions preserving ~$100M+ trusts each, with forward catalysts clustered May-June 2026.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 13, 2026

Overnight SEC filings from May 12-13, 2026, reveal a mixed Q1 2026 earnings landscape across 50 reports, with standout revenue growth in small-caps like SS Innovations (+117% YoY), SOLV Energy (+66% YoY), and ASIAFIN (+105% YoY), contrasted by declines in DarioHealth (-17% YoY), Hughes Satellite (-11% YoY), and Spectral AI (-40% YoY R&D revenue). SPAC activity surges with new IPOs (Starlink AI $100M, West Enclave $115M total), extensions (Aquaron to 2027, GP-Act III to Nov 2026), and non-redemptions boosting deal prospects. Annual meetings dominate with strong approvals (Lockheed Martin 86% quorum, Innospec 91%), signaling governance stability, while capital allocation favors buybacks (News Corp $1B program), tenders (Expensify $25M), and debt refinancings (Tempus AI $350M notes, SOLV post-IPO paydown). Biotech firms like Zenas, Anteris, and Azitra report widened losses from R&D but bolstered cash via raises ($320M Anteris, $419M Zenas), extending runways to 2029. Portfolio trends show margin expansions in National Vision (+760 bps adj op margin to 10.2%) and Regis (+improved op income despite -8% rev), but compressions elsewhere; forward catalysts cluster in H2 2026 trials/data readouts. Implications: Bullish for SPACs and growth small-caps pre-market, cautious on biotechs with burn rates, watch guidance reaffirms like Cigna's $30.35 EPS.

31 high priority 19 medium 50 total filings
· daily

Big Pharma Approvals — May 12, 2026

The FDA approval period from May 12 to May 12, 2026, featured 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other approval, representing a quiet week dominated by a single bullish signal from Big Pharma. GENENTECH INC secured a label expansion for OCRELIZUMAB (OCREVUS), categorized as a fallback/other approval, signaling moderate upside potential (strength 5/10, materiality 5/10) for the sponsor's established franchise. No dominant therapeutic area theme emerged from this single event. The highest-conviction signal is GENENTECH INC's OCRELIZUMAB label expansion, which could support sustained revenue contribution amid limited disclosure on peak sales, exclusivity, or pricing. A key risk/watch item is the lack of disclosed commercial details, warranting monitoring for post-approval uptake and competitive dynamics.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 12, 2026

Across 39 filings in the S&P 500 Technology stream (with some adjacent sectors), Q1 2026 results reveal robust revenue growth averaging +22% YoY in reporting companies (e.g., Ducommun +9%, Madison Air +33.8%, NVIDIA FY26 +65%), but mixed profitability with margin expansions in industrials (+70 bps Ducommun) offset by widening losses in biotechs (Immunome +29% YoY net loss). Institutional 13F-HR filings (13 total) show heavy concentration in tech/semiconductors (NVDA, AMD, Broadcom top holdings across Azimuth, Belvedere, Ilmarinen), signaling sustained conviction amid AI/data center tailwinds. Positive AGMs (Cadence 90-99% approvals, Atmus >95%) and capital raises (Madison IPO $2.58B net, AIM warrant exercise $3.6M) underscore shareholder alignment, while takeover tensions (Diana's 14.7% Genco stake, proxy fight June 18) add volatility. Forward guidance is optimistic where provided (Madison FY26 sales $3.75-3.85B, Immunome cash to 2028), but liquidity risks emerge in cash-burners (Imunon -45% QoQ cash). Sector themes highlight tech growth resilience vs. operational pressures in smaller names, positioning AI/semicon leaders for outperformance.

13 high priority 26 medium 39 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 12, 2026

Across 40 filings from NASDAQ-100 related entities on May 12, 2026, Q1 2026 earnings dominate with robust revenue growth in aerospace/defense (Ducommun +9% YoY), HVAC (Madison +33.8% YoY), IT services (Intellicheck +13% YoY, Intelligent Protection +15.2% YoY), and shipping (Genco EBITDA +331% YoY), but mixed profitability due to cost pressures and biotech losses widening (Immunome +29%, Imunon +3.6%). Margin expansions noted in 4/10 reporting companies (e.g., Ducommun gross +70 bps, Madison Adj EBITDA +89 bps), while cash positions declined QoQ in 7/12 cases amid inventory builds and R&D spends. Forward-looking catalysts include Madison FY2026 guidance ($3.75-3.85B sales), biotech trials (PepGen 2H 2026 data, Imunon Phase 3 2029), and AGMs (Genco/Dyadic June 18, NVIDIA June 24). Institutional 13Fs (Intel, AMD, Belvedere) show heavy tech/options exposure with no major shifts, signaling steady conviction. Shipping M&A battle (Diana 14.7% Genco stake, proxy fight) and capital raises (Madison IPO debt repay, AIM $3.6M warrants) highlight deleveraging trends. Portfolio implication: overweight aero/IT growth, monitor biotech liquidity and shipping takeover premium.

14 high priority 26 medium 40 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 12, 2026

Across 50 filings in the USA S&P 500 Financials stream, 30+ are 13F-HR disclosures from asset managers and institutions revealing overwhelming concentration in mega-cap tech (Apple, NVIDIA, Amazon topping 80% of portfolios, avg 30-43% allocation) and ETFs, signaling strong conviction in tech amid financials focus. Earnings reporters (7 high-materiality 8-Ks) show mixed Q1 2026 trends: revenue growth averaging +11% YoY in 5/7 (Ducommun +9%, Qnity +18%, Green Dot +17%, Optex flat 6-mo, BETA +5.6%), but net losses widening in growth names (BETA to $122M from $78M) and GAAP declines (Qnity NI -19%). Guidance mostly raised (Qnity FY sales $5.225-5.375B +~10%, Optex FY rev $43-45M +5-9%), with margin expansions in industrials (Ducommun +70bps, Optex +390bps). Key developments include eBay rejecting $20B GameStop bid (confident in $80B GMV standalone), Green Dot B2B-driven +109% NI amid acquisition progress, and S&P Global Mobility spin-off Investor Day. Portfolio-level: Financial institutions underweight sector peers, overweight tech (e.g., National Pension $13B+ in top tech), implying rotation risks; capital allocation lean with News Corp $1B buyback and UGI €300M notes.

6 high priority 44 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 12, 2026

The 50 filings for USA S&P 500 Consumer Staples stream reveal limited direct sector exposure, with institutional 13F-HR disclosures (22/50 filings) overwhelmingly concentrated in mega-cap tech (e.g., Apple, Nvidia, MSFT comprising 40-60% of portfolios across Circle Wealth, Channel Wealth, Sittner & Nelson, etc.), signaling broad investor preference for growth over defensive staples. Operational results from available Q1 2026 data show mixed trends: revenue growth in outliers like Qnity Electronics (+18% YoY to $1.3B, organic +17%) and New Mountain Net Lease (+11% YoY revenues), but declines in Under Armour (-1% Q4 YoY) and SideChannel (-16.8% Q2 YoY), with margin compression averaging -200-400 bps in pressured names amid cost inflation. Leadership changes dominate non-13F filings, with positive transitions (Diodes Chairman retirement after scaling revenue 10x, Standard Motor new COO) contrasting HF Sinclair's CEO/CFO separations (severance $4.7M, ongoing leave). Forward guidance includes Qnity's raised FY2026 sales ($5.225-5.375B, Adj EPS $3.80-4.14) and Under Armour's FY2027 slight revenue decline but +220-270 bps margins; annual meetings (Pangaea, Clearwater, Steele Bancorp) passed all items with strong majorities. Capital allocation leans conservative (e.g., no debt at Verde Clean Fuels with $54M cash), while M&A progress (Apellis HSR clearance for $41/share + CVR tender) and pipeline catalysts (Prelude Therapeutics IND mid-2026) offer spots of alpha. Overall, sparse staples-specific insights suggest sector stability via ETF holdings, but portfolio-level tilt to tech implies rotation risks if staples rally.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 12, 2026

The 50 filings for USA S&P 500 Industrials stream are dominated by 37 neutral 13F-HR disclosures from global managers (US, Hong Kong, Australia, Singapore), revealing Q1 2026 portfolios heavily concentrated in tech mega-caps (Apple, MSFT, NVDA topping 80% of filings, e.g., Circle Wealth 43% AAPL) and broad ETFs, signaling sustained institutional conviction in growth equities amid diversified risk via treasuries/quality factors. Operational filings (13 total) show mixed but resilient industrials trends: Ducommun (aerospace/defense) posted record Q1 revenue +9% YoY to $209M with gross margins +70bps to 26.9% and adj EBITDA +19%; Venture Global (LNG/infra) surged revenue +59% YoY to $4.6B, raising FY26 EBITDA guidance to $8.2-8.5B with new $8.6B project financing. Contrasts include sharp declines (VenHub revenue -86% YoY, Next Bridge -11% YoY with no reserves/employees) and ongoing losses (Verde Clean Fuels improved net loss to $2.4M YoY but cash burn persists; BCSF NII -8% QoQ, NAV -2.2%). Capital allocation leans supportive (BCSF $0.42 dividend covered, Venture $0.02/share, issuances for growth), with catalysts like S&P Global Mobility Investor Day (May 12, 2026) and leadership positives (Diodes new Chair). No insider transactions reported across filings; sector portfolio-level trends highlight aero/defense outperformance vs. energy explorers' weakness, positioning industrials for infra/LNG tailwinds but destocking risks.

7 high priority 43 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 12, 2026

Batch of 16 filings dominated by neutral 13F-HR disclosures from institutions (e.g., United Super $5.3B AUM, Stokes $969M, Chesapeake $126M) showing stable Q1 2026 holdings heavily skewed to tech mega-caps like NVDA ($327M top at United Super), AAPL, AMZN despite Energy sector focus, signaling broad market conviction in AI/big tech over pure energy plays. Energy sector highlights include SLB's $2B senior notes issuance at 4.55-5.15% (positive capital access for services/growth), Exxon's defensive DEFA14As rebutting proxy opposition to Texas redomicile (mixed governance risks), and Dorchester Minerals' annual meeting tomorrow with investor presentation. Operational trends mixed: Ampco-Pittsburgh Q1 sales +3.9% YoY to $108.3M and backlog to $345.5M on $124M orders but net loss $0.9M vs profit $1.1M YoY, Adj EBITDA margin -70bps to 7.4%; Orchestra BioMed revenue -87% YoY to $110k with loss widening 10%; XOMA income -23% YoY but net income +89% to $4.5k via gains; AOXY revenues +2% YoY. Cash flow improvements prominent (Ampco OCF +$7M YoY to +$1.7M, XOMA +178% to $6.1k, AOXY +37%). No insider trading activity noted across filings; capital allocation favors debt raises (SLB) and pension funding (Ampco fully funded). Portfolio-level: 10/14 new 13Fs neutral with sole discretionary holdings, no put/call shifts; implications point to energy tactical plays amid institutional tech stability.

4 high priority 12 medium 16 total filings
· daily

US Material Events SEC 8-K Filings — May 12, 2026

Across 50 US SEC filings from May 12, 2026, dominant themes include widespread executive transitions (24 cases, ~48% orderly retirements/appointments signaling continuity), robust annual meeting approvals (17 filings, avg 90%+ support for directors/equity plans/auditors), aggressive financing (18 cases: debt refinancings, equity raises, facilities with lower rates/costs), and M&A/JV activity (12 deals, total ~$2.5B+ value). Period-over-period trends show strong revenue acceleration in industrials/energy/semiconductors (e.g., SOLV +66% YoY Q1 rev to $677M, Arteris +39% YoY to $22.9M, Nextpower +20% FY26 to $3.56B) but mixed margins (improvements in SOLV gross +310bps to 17.6%, compressions in OptimizeRx amid macro pressures). Guidance upgrades in 7 firms (e.g., SOLV EBITDA $435-455M, Collegium rev $865-895M) contrast isolated downgrades/dilution risks; biopharma mixed with trial misses offset by partnerships (Arvinas $85M upfront). Portfolio-level: Semis/tech resilient (positive sentiment 80%), financials bolstering liquidity, health sector catalyst-rich but volatile; implies bullish rotation to growth industrials, caution on leadership-vacant energy.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 12, 2026

Across 50 SEC filings from Dow Jones 30-related streams, institutional 13F-HR reports (32/50) reveal overwhelming conviction in US tech giants (Apple, Microsoft, NVIDIA, Amazon topping nearly every portfolio, with aggregate values exceeding trillions), signaling bullish portfolio positioning amid ETF dominance for broad market exposure. Operational filings highlight robust LNG sector growth (Venture Global revenue +59% YoY to $4.6B, EBITDA guidance raised to $8.2-8.5B), accretive M&A (Global Net Lease acquiring Modiv for $535M, +4% AFFO accretive, Q3'26 close), and mixed small/mid-cap results (e.g., Optex revenue -10% YoY but margins +390 bps to 35.2%, FY guidance raised). Period trends show revenue growth in energy (avg +59% YoY) contrasting margin improvements in industrials/manufacturing (+390 bps) but declines in consumer/small caps (e.g., VenHub -86% YoY). Capital allocation favors dividends (Venture Global $0.02/share, Sound Financial +11% YoY to $0.21/share) and debt raises (Bain Capital $350M notes). Forward catalysts include Investor Days (S&P Global Mobility May 12, 2026), merger approvals (Volato/M2i), and court hearings (Honest Co. July 13, 2026), with neutral sentiment dominating 13Fs but positive M&A/earnings outliers driving actionable alpha in energy/REITs.

9 high priority 41 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 12, 2026

The May 12, 2026, SEC filings reveal a deluge of 13F-HR reports (over 30) from global institutions, showcasing overwhelming conviction in US tech giants like NVIDIA, Apple, Amazon, and semiconductors, with portfolio concentrations up to 43% in single names like AAPL, signaling sustained bullishness amid AI hype. Earnings and operational 8-Ks present mixed pictures: aerospace/defense names like Ducommun posted record revenue (+9% YoY) and margin expansion (+70 bps), while electronics firms like Qnity saw sales surge (+18% YoY) and raised FY guidance despite GAAP EPS drops. Capital markets activity thrives with IREN's $2.6B convertible notes pricing (positive) and eBay's rejection of GameStop's $20B bid, affirming standalone strength. Risks emerge in niche areas: BETA Technologies' losses widened dramatically (net loss to $122M from $78M YoY), Next Bridge Hydrocarbons reported revenue declines (-11% YoY) with zero reserves, and Maison Solutions faces Nasdaq delisting risk for missing annual meeting. Forward guidance leans optimistic in select industrials (e.g., Optex FY revenue up to $45M), but consumer segments weaken (Green Dot GDV -8% YoY). Portfolio-level trends highlight margin resilience in defense (+70 bps avg across Ducommun/Optex) versus compression elsewhere, positioning aerospace as a relative outperformer amid industrial softness.

6 high priority 44 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 12, 2026

The May 12, 2026, filings for S&P 500 Consumer Discretionary reveal heavy institutional conviction via 40+ 13F-HRs, with Amazon.com as a top holding across 12 portfolios (e.g., 17.9%/$134M at GCQ Funds, $999M at Mitsubishi UFJ, $306M at United Super), alongside Uber (14%/$105M at GCQ) and exposure to eBay peers, signaling sustained allocation to e-commerce and ride-sharing amid neutral sentiment. Operational highlights include Aramark's robust Q2 FY2026 results (+15% YoY revenue to $4.9B, +12% organic, +40% adj EPS to $0.49, +116% FCF), eBay's rejection of GameStop's non-binding $20B debt-financed bid citing $80B 2025 GMV standalone strength, and mixed hospitality metrics like Ashford Hospitality's hotel sale improving pro forma net loss -4% YoY and SmartStop Self Storage's occupancy dip -70bps YoY to 92.3%. Period trends show growth divergence: 15-115% YoY revenue surges in services/infra (Aramark, JFB Construction, Cardinal Infrastructure) vs declines in volumes/occupancy (-11% rev at Next Bridge, rates down at SmartStop). Forward guidance is optimistic (e.g., Figure's Q2 vol $3.8-4.1B, Cardinal FY rev raised to $675-685M, Aramark leverage <3x FYE), with capital returns via Aramark's $25M buyback/$55M debt paydown/$0.12 dividend and Sound Financial's dividend hike to $0.21/share. Executive risks emerge (HF Sinclair CEO separation $4.7M severance, CFO leave), but no broad insider selling; overall, bullish flows favor selective e-comm/services overweight with hospitality watch.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 12, 2026

Across 50 filings dominated by Q1 2026 13F-HR disclosures, institutional investors maintain heavy overweight in mega-cap tech (AAPL top holding in 20+ managers, NVDA/LLY in select like Matthew 25's $25M LLY stake), signaling broad conviction amid limited S&P 500 Healthcare direct exposure beyond ETF proxies. Biotech filings (ProMIS, CalciMedica, Achieve, Sagimet, Unicycive, Harvard Bio, Pacira) reveal YoY net loss narrowing or swings to profit (e.g., Sagimet -41%, Achieve -20.6%, CalciMedica +$10M swing) driven by R&D cuts (-54% Sagimet, -17% CalciMedica), offset by $700M+ in fresh financings extending runways to 2027-2028. Revenue trends mixed: strong growth in sensors (VPG +17.6% YoY) vs declines in life sci tools (HBIO -4.7% YoY), with gross margins improving (HBIO +300bps to 59%). Forward catalysts cluster in H2 2026 (FDA feedbacks, trial readouts), while Pacira's proxy fight highlights activist risks. Non-health financials/REITs show deposit/asset growth (CB Financial +2.7% deposits QoQ) but expense pressures (New Mountain +27% YoY). Overall, actionable alpha in biotech pipelines undervalued vs sector, with institutional tech tilt implying healthcare laggard status.

11 high priority 39 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 12, 2026

Across 12 DEF 14A filings dated May 12, 2026, a dominant theme is clustered June 2026 shareholder meetings (10/12 between June 2-25) for director elections (11/12), auditor ratifications (9/12), say-on-pay votes (4/12), and advisory agreement approvals amid control changes or M&A (5/12 funds/ETFs). Period-over-period trends reveal stark contrasts: NVIDIA's explosive FY2026 revenue +65% YoY to $215.9B and EPS +67% to $4.90 outpace peers, while CarMax EPS plunged -47.7% YoY to $1.68 amid sales declines and impairments, Apogee sales edged +3% YoY but op margin contracted -270 bps to 6.0%, and funds show no financial declines but advisor disruptions. Mixed sentiment prevails (4/12 mixed), with high materiality in growth outliers (NVIDIA, CarMax 9/10) and fund transitions (MFS, Tavia 9/10). No insider trading or capital allocation shifts noted across filings, but director ownership at Dyadic (20.9%) signals alignment. Market implications include governance catalysts for volatility, potential continuity post-approvals boosting stability in funds/tech, and relative outperformance opportunities in high-growth names like NVDA versus cyclical decliners like KMX/APOG. Portfolio-level pattern: Margin compression in 3/4 detailed financials (avg -150 bps) despite uneven revenue growth, highlighting cost pressures amid transitions.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 12, 2026

Three S-1 filings on May 12, 2026, highlight an active IPO pipeline with a SPAC (Tidewise), a distressed follow-on (Sunshine Biopharma), and a pre-IPO tech play (Amesite), focusing on healthcare/biotech/AI themes amid small-cap volatility. Amesite stands out with a 17.9% YoY net loss improvement to $3.617M in FY2025 (ended June 30, 2025) versus $4.403M in FY2024, signaling operational progress despite going concern doubts. Sunshine eyes $5M net proceeds from 5.825M units at $1.03 to boost pro forma cash 55% to $14.16M from $9.12M (Dec 31, 2025), but faces Nasdaq delisting risk with bid price flirting below $1.00. Tidewise's SPAC IPO at $10/unit details extensive dilution/redemption scenarios (up to 100%) with pro forma as of Oct 31, 2025, typical for blank-checks. Portfolio-level pattern: Mixed sentiment dominates (2/3 filings), with loss narrowing in Amesite as sole positive period trend, but pervasive risks like dilution, delisting, and cash burn underscore caution for IPO investors targeting turnarounds. No insider transactions noted, but concentrated ownership in Sunshine (Dr. Slilaty 100% Series B Pref votes) flags control dynamics. Implications: Watch for quick catalysts like Nasdaq decisions and financing closes in volatile small-cap healthcare/AI space.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — May 12, 2026

Across 50 filings in the 'Global High Priority Market Events' stream (US SEC and Indian exchanges, dated May 12, 2026), dominant themes include multiple corporate insolvencies and restructurings in Indian firms (e.g., Morarjee Textiles resolved, Arshiya with ₹67B claims), positive buyback announcements (Onward Technologies ₹18Cr, Garware ₹110Cr), and mixed Q1 2026 results with revenue growth averaging +35% YoY in outperformers like Rocket Companies (+167%) and SOLV Energy (+66%) but declines in consumer-facing names like Sleep Number (-19%). Period-over-period trends show 18/25 10-Qs with YoY revenue growth (avg +44% in positives), but margin compression in 12 cases (avg -150bps in mixed sentiment firms); capital allocation leans bullish with buybacks and dividends up YoY (e.g., Sound Financial +11% dividend). Critical developments: NCLT resolutions/takeovers (AVI open offer at ₹33/share), SPAC amendments, and raised guidance (SOLV EBITDA to $435-455M). Portfolio implications: Favor buyback plays and strong Q1 industrials amid insolvency risks in India; sector rotation toward semis/energy with hedges on consumer weakness.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 12, 2026

Across 50 Q1 2026 10-Q filings, mixed sentiment prevails in 44/50 cases, reflecting revenue volatility with 18 companies posting YoY growth (avg +35%, led by Rocket Companies +167% and Venture Global +59%) but 12 showing sharp declines (avg -45%, worst VenHub -86% and Longduoduo -76%). Net losses narrowed in 22 biotechs/pharmas (avg improvement 25%) via cost cuts, though cash burn persists; financials/banks saw NII growth in 5/8 (avg +20%) amid deposit/loan expansion. Balance sheets strengthened via equity raises in 15 firms (total ~$300M+ proceeds), but 10 reported cash declines >20% QoQ signaling liquidity strains. Capital allocation favors dividends (e.g., Sound Financial +11% payout) over buybacks, with no major M&A but ongoing projects like Venture Global's LNG. Portfolio trend: Margin resilience in growth names (avg +150bps gross margins) vs compression in decliners (-200bps avg), implying rotation to outperformers like Ducommun (+216% op income) amid sector dispersion.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 12, 2026

Three small-cap companies—Maison Solutions Inc., Beauty Health Co (SKIN), and BIO-Key International Inc (BKYI)—disclosed Nasdaq listing non-compliance notices in 8-K filings dated around May 6-12, 2026, signaling acute regulatory distress in the USA Trading Suspensions stream. Overarching themes include governance failures (annual meeting), reporting delays (late 10-K), and market price deficiencies (bid < $1), with all exhibiting negative sentiment and high materiality (9-10/10). No enriched period-over-period financial trends (YoY/QoQ revenue, margins) were detailed, but late filings and low bids imply operational deterioration and potential QoQ bid price declines exceeding 10 consecutive days for BKYI. Critical developments: imminent trading suspension for BKYI on May 13, 2026, with delisting to OTC, while others seek compliance plans; portfolio-level pattern shows 3/3 firms at delisting risk, eroding liquidity and shareholder value. Market implications: heightened volatility, short opportunities pre-suspension, and avoidance for long portfolios amid absent positive insider activity or capital returns data.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 12, 2026

Across 36 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq listing non-compliance and imminent delistings in small caps (4/36 filings: Maison Solutions, Beauty Health, BIO-Key, with suspensions starting May 13, 2026), heavy reliance on dilutive equity/debt conversions and warrant issuances (6/36: Functional Brands, Securetech, Firefly, Perfect Moment, XCF Global), and ongoing debt forbearances signaling liquidity strains (Vivakor with $11.9M outstanding). Counterbalancing positives dominate larger caps with debt refinancings at lower rates (e.g., Sezzle -290bps spread, Procaccianti to 6.50%, Cinemark -0.25%, DHI extension to 2029), asset sales for non-dilutive cash (MacroGenics $122.5M), and M&A/debt-to-equity swaps (Diversified $1.175B acquisition, NSTS $73.7M buyout). Period-over-period trends limited but notable: OptimizeRx Q1 rev -10% YoY to $19.8M but adj EBITDA +120% to $3.3M, cash -14% QoQ to $20.2M; American Woodmark plant closure for $7.5M annual savings but $36-40M charges. No outright bankruptcies, but 11/36 exhibit clear distress signals vs 15 positive financings, indicating micro-cap vulnerability amid proactive deleveraging in mid/large caps. Forward catalysts cluster in Q2-Q3 2026 (compliance plans by late June, deal closes Q3), with portfolio-level margin trends unavailable but dilution risks elevated in 20% of filings.

36 high priority 36 total filings